

Biogen Idec – Poised to Grow Beyond MS

<https://marketpublishers.com/r/BFADB2E346AEN.html>

Date: July 2013

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: BFADB2E346AEN

Abstracts

BiIB's efforts towards diversification are finally taking going to take shape from this year onwards with approvals of drugs in indications other than Multiple Sclerosis (MS) while BiIB's supremacy in MS to remain. Positive new data from ELOCTATE (long-acting rec. Fact VIII Fc, hemophilia A) and ALPROLIX (long-acting rec. Fact IX Fc, hemophilia B – Hemo B) presented at the XXIV ISTH Congress reinforces their advantages/potential safety, efficacy, and pharmacokinetic profile. Last month, FDA approved the first short-acting rFIX, Baxter's Rixubis for routine prophylaxis of Hemo B; however, we expect the long-acting products to lead/ change the current hemophilia treatment paradigm. Our report released on Feb. 13, 'Hemophilia – New Therapies and Changing Market Dynamics' has an in-depth analysis of the clinical efficacy, safety, and commercial prospects of the Marketed and late-stage products in development... For more detail, please read our report released on July 8, 2013, titled, "Poised to Grow Beyond MS".

I would like to order

Product name: Biogen Idec – Poised to Grow Beyond MS

Product link: <https://marketpublishers.com/r/BFADB2E346AEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BFADB2E346AEN.html>